You are here: Industry Insights > Genentech

News List

First-line use of Roche’s Tecentriq given priority review pharmatimes
July 09, 2018
US regulators are undertaking a priority review of Roche unit Genentech’s PD-L1 inhibitor Tecentriq, in combination with Avastin and standard chemotherapy for some patients with lung cancer.
Genentech and Microbiotica to develop new IBD medicines pharmaceutical-technology
June 13, 2018
Genentech has formed a multi-year strategic alliance with Wellcome Sanger Institute’s Microbiotica to address inflammatory bowel disease (IBD).
FDA Approves Genentech’s Rituxan (rituximab) for Pemphigus Vulgaris drugs
June 12, 2018
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Rituxan (rituximab) for the treatment of adults with moderate to severe pemphigus vulgaris (PV),
Lodo Therapeutics Corporation Forms Multi-Target Strategic Collaboration with Genentech pharmafocusasia
May 14, 2018
Lodo Therapeutics Corporation, a drug discovery and development company focused on identifying and producing unique,
GSK Recruiting Score: Genentech's Kevin Sin to Help Drive R&D and M&A biospace
April 19, 2018
GlaxoSmithKline Chief Executive Officer Emma Walmsley continues to hone her leadership team with a hire who will focus on potential research and development deals.
Kineta Chronic Pain Inks License Deal with Genentech for Over $359 Million biospace
April 18, 2018
Seattle-based Kineta Chronic Pain, a subsidiary of Kineta, signed an exclusive option and license deal with Genentech, a Roche company.
FDA Grants Genentech’s Hemophilia Drug Breakthrough Therapy Designation Despite Reports of Patient Deaths biospace
April 18, 2018
The U.S. Food and Drug Administration (FDA) granted Genentech, a Roche company, Breakthrough Therapy Designation for Hemlibra (emicizumab-kxwh) for hemophilia A without factor VIII inhibitors.
Five Deaths in Genentech's Hemlibra Patients biospace
March 29, 2018
The American Hemophilia Federation and the National Hemophilia Foundation announced that they have contacted Genentech, a Roche company
Genentech's Late-Stage Trial Data Shows Combination of Tecentriq and Avastin Helps NSCLC Patients Live Longer Genentech's Late-Stage Trial Data Shows Combinatio
March 27, 2018
Genentech plans to seek regulatory approval for compliance with lung cancer treatment because...
FDA Approves Genentech’s Lucentis (ranibizumab injection) 0.3 mg Prefilled Syringe for Diabetic Macu biospace
March 22, 2018
Genentech, Inc., a member of the Roche Group today announced that FDA approved the Lucentis® 0.3 mg prefilled syringe (PFS) as a new method of administering the medicine to treat all forms of diabetic retinopathy

Previous page 1 2 3 4 5 6 7 8 Next page